(Total Views: 132)
Posted On: 05/07/2024 4:54:21 PM
Post# of 90
NetworkNewsBreaks – PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy
PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (‘ASD’),” said Howard Weisman, CEO of PaxMedica, further emphasizing the company’s efforts to advance healthcare solutions globally. “We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year. We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (‘ASD’),” said Howard Weisman, CEO of PaxMedica, further emphasizing the company’s efforts to advance healthcare solutions globally. “We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year. We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
